Diabetes Connections | Type 1 Diabetes

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.

What's Next for Dexcom? G8, New Research & Your Questions with Jessica Castle, VP Global Medical Affairs 10/11/2026

In the News... Experimental new peptide for T2D, low-carb studies in kids, GLP-1 pill info, gaps in CGM access, fashion line honors a T1D icon, and more! 10/06/2026

In the News... Experimental new peptide for T2D, low-carb studies in kids, GLP-1 pill info, gaps in CGM access, fashion line honors a T1D icon, and more! This week on Diabetes Connections In the News… A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2. Plus, new data on Lilly’s daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine. And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar. Check out all of Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page This week on Diabetes Connections In the News… A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2. Plus, new data on Lilly’s daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine. And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar. All that and more, coming up! It’s all coming up right after this. (AD BREAK) Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Super excited to tell you that we have joined the Health Podcast Library! Over the years, I’ve been asked to join a lot of networks – and I’ve thought about starting my own – but this is the first one that made sense to me. Health Podcast Library is a free place to find health podcasts from credible people and organizations. The creators and organizations producing each show are reviewed before it is listed. They believe sourcing matters. They don’t pay me to be there and I’m proud to say I’m the first Diabetes Show featured on the Library to sign their The Health Content Integrity Pledge is a commitment from creators across all health topics and platforms to continuously work toward embedding evidence-based principles in their content creation and platform management. As creators of health-related content, we recognize our responsibility to provide accurate, transparent, and credible information that helps people make informed decisions about their health and well-being. Go check it out and if you’re a health podcaster, consider joining. https://healthpodcastlibrary.com/ Health podcast networks Okay.. our top story this week: XX Eli Lilly says an experimental drug combination helped people with obesity or overweight and type 2 diabetes lose an average of 23.3% of their body weight over 48 weeks, while also improving A1C. The treatment, called eloraTZP, combines the experimental drug eloralintide with Lilly’s approved diabetes and weight-loss medication Zepbound. At the highest dose, participants lost an average of 54.1 pounds. The results are notable because people with type 2 diabetes typically lose less weight with obesity medications than people without diabetes. The study included 367 adults with type 2 diabetes and obesity or overweight. The combination targets three hormones involved in blood sugar, digestion and appetite: GIP, GLP-1 and amylin. Side effects, mainly gastrointestinal, were more common with the combination, and as many as 27% of participants taking eloraTZP stopped treatment. Lilly plans to begin phase 3 trials later this year. XX New research suggests that for people with type 1 or type 2 diabetes, keeping glucose as steady as possible may not always translate into a better quality of life. In a study of 400 people with diabetes, researchers found that spending more time in the normal glucose range was associated with better quality of life the following day. Surprisingly, greater glucose variability was also linked to better next-day well-being, as long as glucose remained within safe limits. The findings, presented at the European Association for the Study of Diabetes annual meeting in Milan, do not suggest that high or low blood sugar is beneficial. Instead, researchers say they may point to a tradeoff in diabetes management: the effort and restrictions involved in trying to eliminate every glucose fluctuation could sometimes interfere with everyday activities and enjoyment of life. The study combined continuous glucose monitor data with daily assessments of mood, energy, sleep, stress and overall well-being. https://www.sciencedaily.com/releases/2026/09/260927225019.htm XX New guidance from the American Diabetes Association and European Association for the Study of Diabetes puts a major focus on correctly diagnosing type 1 diabetes in adults. The report says about 40% of people diagnosed with type 1 after age 30 are initially misdiagnosed as having type 2 diabetes. It emphasizes that type 1 can develop at any age and that adults with the condition may have overweight or obesity, so age and body size alone shouldn’t be used to determine diabetes type. The updated guidance recommends islet autoantibody testing when type 1 diabetes is suspected and, in some cases, C-peptide testing to determine how much insulin the body is still producing. It also discourages use of the term “LADA,” or latent autoimmune diabetes in adults, saying these cases are better classified as type 1 diabetes. The report also includes expanded guidance on diabetes complications, cardiovascular risk, obesity, exercise, nutrition and mental and emotional health. https://www.medscape.com/viewarticle/guidance-type-1-diabetes-management-adults-updated-2026a1001080 XX Eli Lilly says its once-daily GLP-1 pill Foundayo, also known as orforglipron, lowered A1C and weight while demonstrating cardiovascular safety in adults with type 2 diabetes and obesity or overweight who were at increased risk for heart problems. In the study, participants taking Foundayo lowered their A1C by 1.6 percentage points and lost an average of 8.8% of their body weight, or nearly 18 pounds, after one year. Those taking long-acting insulin lowered A1C by 1 percentage point and gained an average of 1.7% of their body weight. Foundayo was also found to be at least as safe as insulin glargine when researchers looked at major cardiovascular events, including heart attack and stroke. The study also reported improvements in blood pressure, waist circumference and cholesterol, along with a slower decline in kidney function. The results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet. https://www.fiercepharma.com/pharma/lilly-gives-deeper-glimpse-foundayos-heart-helping-odds-diabetes-obesity-phase-3 XX A large Norwegian study found that type 1 diabetes diagnoses among young children increased after the country introduced routine rotavirus vaccination in 2014. Researchers followed more than 740,000 children and found that the rate of type 1 diabetes before age 5 was 11% higher than expected based on trends before the vaccine was introduced. The findings were presented at the European Association for the Study of Diabetes annual meeting and published in Diabetologia. Importantly, the study does not show that the rotavirus vaccine causes type 1 diabetes. When researchers compared fully vaccinated children directly with unvaccinated children, the difference in type 1 diabetes risk was not statistically significant. Researchers had been studying the vaccine because infections, including rotavirus, have been investigated as possible environmental factors affecting type 1 diabetes risk, and previous studies have produced conflicting results. https://www.news-medical.net/news/20261001/Type-1-diabetes-incidence-rose-by-1125-after-rotavirus-vaccine-rollout-in-Norway.aspx XX A large study of children with type 1 diabetes found that very low- and low-carbohydrate diets were associated with better blood sugar control and lower insulin needs, without evidence of impaired growth or increased rates of severe low blood sugar or diabetic ketoacidosis. The research included more than 45,000 children ages 1 to 17 and used up to 25 years of data. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan. Children eating fewer carbohydrates also had smaller increases in BMI and A1C over time compared with those eating standard or higher-carbohydrate diets. However, researchers emphasized that this was an observational study, meaning it cannot prove that eating fewer carbohydrates caused these improvements. They say more research is needed to determine the long-term safety of these diets and how much carbohydrate may provide benefits while still supporting good nutrition and food variety. https://medicalxpress.com/news/2026-10-carbohydrate-diets-linked-health-benefits.html XX A structured diet and exercise program helped about half of younger adults with type 2 diabetes achieve remission, according to research presented at the European Association for the Study of Diabetes annual meeting in Milan. The study focused on adults ages 18 to 45 with obesity and early-onset type 2 diabetes, a form of the condition associated with faster progression and earlier complications. Participants in the program followed a low-calorie diet of 800 to 900 calories per day for 12 weeks, along with supervised aerobic and strength training, before transitioning to a weight-maintenance diet and independent exercise. At 24 weeks, researchers measured how many participants had an A1C below 6.5% without taking glucose-lowering medication for at least 12 weeks. The researchers compared those results with participants receiving usual diabetes care. https://medicalxpress.com/news/2026-10-calorie-diet-early-onset-diabetes.html XX The FDA has approved Eli Lilly’s Onswik, a once-weekly long-acting insulin for adults with type 2 diabetes. Instead of taking a daily basal insulin injection, people using Onswik will take one injection per week, potentially eliminating more than 300 injections a year. In studies involving more than 3,400 adults with type 2 diabetes, Onswik lowered A1C by amounts comparable to daily long-acting insulin. Onswik is expected to become available in the U.S. in the coming months in pre-filled insulin pens. The insulin is approved for type 2 diabetes only and should not be used by people with type 1 diabetes because of an increased risk of severe low blood sugar. Onswik has already been approved in Europe, Japan and Mexico. Onswik joins Novo’s Awiqly – which I have to say are two of the more entertaining drugs names we’ve seen this year. https://www.reuters.com/legal/litigation/us-fda-approves-lillys-once-weekly-insulin-injection-type-2-diabetes-2026-09-24/ XX Two small studies looked at how different physical activity affects glucose levels in people with type 1 diabetes. In one, researchers tracked 110 instances of sexual activity among 12 adults using continuous glucose monitors and found no clinically significant hypoglycemia, even when sex occurred at night. Glucose sometimes rose and sometimes fell, suggesting there isn’t one predictable glucose response to sexual activity. A separate study followed 10 runners with type 1 diabetes as they completed a marathon alongside 10 runners without diabetes. All of the runners with T1D finished, with times comparable to the control group, although one runner had two low blood sugar readings. Researchers also found that CGMs became less accurate during the marathon and suggested using a glucose meter when sensor readings don’t match how a runner feels. Both studies were small, but researchers say the findings could help address fear of hypoglycemia, which can affect everything from exercise to intimacy. http://medicalxpress.com/news/2026-09-marathons-diabetes-safe-small.html#goog_rewarded XX We told you about Beta Bionics iLet new compatibility with Senseonic’s Eversense 365 CGM.. now the companies announce the MINT tubeless pump will also work with the year-long implantable CGM. Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users. The companies have also committed to the integration of mint and Eversense 365 in the future. This partnership underscores Beta Bionics’ and Senseonics’ shared commitment to bringing cutting-edge diabetes solutions to the market, while maximizing choice for people living with diabetes. XX Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes,1 is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom. No word yet on the tubeless Mobi – still waiting to hear from the FDA on that. Tandem Mobi is powered by Control-IQ+ technology, the predictive algorithm that automates insulin delivery. The system uses a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every 5 minutes to help reduce high and low blood sugar. Tandem Mobi also offers multiple wear options, mobile app control through a compatible, personal iPhone,* and a 200-unit cartridge. https://www.businesswire.com/news/home/20260928831177/en/Tandem-Mobi-Automated-Insulin-Delivery-System-Now-Available-in-Twelve-International-Markets XX Many people with type 2 diabetes still face barriers to using continuous glucose monitors, according to a new report from Dexcom. The company surveyed about 2,500 people with type 2 diabetes and more than 800 healthcare professionals across eight countries. More than half of people with diabetes said they knew little about CGM as a management option, while healthcare professionals pointed to insurance coverage and reimbursement as major barriers to access. Among people with type 2 diabetes already using CGM, 94% said the technology helped them manage their diabetes more independently and 91% said they used CGM data to help make treatment decisions. The report also found limited awareness of using CGM alongside GLP-1 medications: 72% of people with type 2 diabetes surveyed did not know the two could be used together. The findings were released by Dexcom ahead of the European Association for the Study of Diabetes annual meeting in Milan. XX Dexcom is facing a handful of lawsuits, alleging the company's CGMs malfunctioned and caused severe medical emergencies in children. The latest lawsuits involve a 7-year-old California girl and a 10-year-old Tennessee girl who were both hospitalized after their Dexcom G7 devices allegedly failed to accurately report blood glucose levels. The legal firm behind 11 of these suits say they involved G7 and G6 CGMs with plantiffs in six states. https://www.mddionline.com/diabetes/dexcom-faces-lawsuit-alleging-device-failures-endangered-children XX Frances Valentine, the fashion brand created by the late Kate Spade and her friend Elyce Arons, is dipping into the glamorous world of old Hollywood with a new Mary Tyler Moore collection that pays homage to the actress. The limited-edition capsule features 20 pieces, including shirts, dresses, tote bags and, of course, shoes, all inspired by the Emmy-winning star’s whimsical, upscale style. Prices start at $48 for a makeup clutch and go up to $498 for wool peacoats. The lineup was co-created with the Mary Tyler Moore Vision Initiative, an organization dedicated to “preserving and restoring vision in people with diabetes,” per the nonprofit’s website. Twenty percent of proceeds from the collection will benefit the cause, which was particularly meaningful to Moore. Type 1 diabetes is an autoimmune condition in which the pancreas produces little or no insulin, while Type 2 diabetes is a metabolic disorder. Other public figures who have spoken about living with Type 1 diabetes include model Lila Moss, Dancing With the Stars pro Rylee Arnold and musician Nick Jonas. The Mary Tyler Moore Vision Initiative was established by Moore’s husband, Dr. S. Robert Levine, following her death in 2017. https://www.hollywoodreporter.com/lifestyle/shopping/mary-tyler-moore-frances-valentine-clothing-collection-2026-1236714592/ XX The FDA has cleared a new app that uses continuous glucose monitor and insulin data to recommend insulin dose adjustments directly to adults with type 2 diabetes who take insulin by injection. The app, called MODI and developed by DreaMed Diabetes, can provide personalized recommendations without requiring a healthcare provider to review or approve each individual dose change. MODI is designed for adults with type 2 diabetes who use long-acting insulin, either alone or with rapid-acting insulin. While automated insulin dosing technology has largely focused on people using insulin pumps, MODI brings automated dosing support to people who use injections. The goal is to help adjust insulin more frequently between healthcare visits, rather than waiting weeks or months for a provider to make changes. Interesting name – there is a type of diabetes called MODY - Maturity-Onset Diabetes of the Young (MODY) is a rare, inherited form of diabetes caused by a single gene mutation that affects how the pancreas makes insulin. https://dreamed.ai/press-releases/dreamed-receives-fda-clearance-for-modi/ /episode/index/show/diabetesconnections/id/43176623

Moving Diabetes Solutions Forward: Beyond Type 1’s Innovation Accelerator 10/04/2026

Sharing T1D With the World: Shannon Boggs on Parenting, Independence & Community 09/22/2026

In the News.. ADA Boycott, new patch pumps, endometriosis and type 2 risk, Zverev wins US Open with T1D, and more! 09/15/2026

In the News.. ADA Boycott, new patch pumps, endometriosis and type 2 risk, Zverev wins US Open with T1D, and more! On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, new patch pump approved, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more.. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Want to let you know about a webinar I’m doing with Abbott later this month. That’s Sept 23 at 7pm ET. We’ll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Join us for Check out all of Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Transcript: On this episode of Diabetes Connections In the news… The ADA conference controversy continues with a boycott now, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more.. It’s all coming up right after this. (AD BREAK) Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are off to Detroit this week for Moms’ Night Out in Bloomfield Michigan. Super excited and as usual I’m getting last minute emails and DMs about respiration from people just finding out about the event. We will always figure it out so drop me a line. But please register now for Seattle next month! Tampa will be open soon as well! Want to let you know about a webinar I’m doing with Abbott later this month. That’s Sept 23 at 7pm ET. We’ll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Great crowd already registered for that, hope you can join us. The link is in the show notes. Okay.. our top story this week: XX Member of the American Diabetes Association… are now boycotting it. The notice of the boycott condemns leadership's actions after five researchers were removed by police from its annual meeting in June. Significantly, The editors of ADA's flagship journal, Diabetes Care, have joined on in support of the boycott. "Manuscripts submitted will not be handled until the boycott is over," said Steven Kahn, MBChB, the journal's editor in chief and one of the five researchers ejected from the meeting in New Orleans, in a LinkedIn post on Thursday. Kahn told MedPage Today that "the journal boycott is like establishing a picket line. The boycott already has hundreds of signatures of people who have pledged to suspend all ADA-related activities, including: Planning or attending any meetings led by ADA leadership or the board, including the 2027 ADA Scientific Sessions Participating in board-led activities regarding the investigation of the meeting's events, or the report generated by the "so-called 'independent' committee" Engaging in all other ADA operations, including presentations, fundraisers, grant reviews, manuscript reviews, journal management, manuscript submissions, and position statements The boycott will remain active until the ADA board of directors permits an independent formal review of the organization's structure and function to ensure it "properly represent[s] its professional membership." If demands are not met, signees plan to align with existing or newly formed medical societies. https://www.medpagetoday.com/endocrinology/diabetes/122977 https://docs.google.com/forms/d/e/1FAIpQLSd4h548X9qXgkVREQ71k2gDHiU8WFAFF78wTnmS20_ntwUM0w/viewform XX A new patch pump is coming to the US.. Beta Bionics, Inc. announces FDA clearance of Mint, the Company’s patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027 Mint is expected to launch exclusively through the pharmacy channel. Also announced, that Eversense 365 is now compatible with Beta Bionics Senseonics expects development of the Eversense 365-iLet integration to be completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements. No word yet on timing for Eversense with Mint. https://www.manilatimes.net/2026/09/14/tmt-newswire/globenewswire/beta-bionics-announces-fda-clearance-of-mint-the-companys-transformative-patch-pump-and-unveils-3d-intelligence-as-its-next-generation-insulin-dosing-algorithm/2424457 XX Seven years after Johns Hopkins researchers discovered a previously unknown immune cell called the “X cell,” they’re now exploring whether that discovery could lead to a new treatment for type 1 diabetes. In preclinical studies, researchers developed an antibody that was able to target and eliminate specific immune cells responsible for attacking the pancreas’s insulin-producing beta cells, while leaving the rest of the immune system intact. The researchers say the approach is especially promising because it could potentially reverse the autoimmune process soon after a type 1 diabetes diagnosis, rather than simply managing blood sugar. The work is still in the early stages and has not yet been tested in people; additional laboratory and preclinical studies are needed before human clinical trials can begin. sclerosis.https://hub.jhu.edu/2026/09/09/federal-funds-support-type-1-diabetes-treatment/ XX A new international consensus recommends routine screening for type 1 diabetes in the general population, offering the first framework for how healthcare providers could put widespread screening into practice. The guidance recommends screening children between ages 2 and 4, with children who test negative screened again at ages 6–8 and 10–15. Screening uses a blood test to look for islet autoantibodies, which can signal that the immune system is attacking insulin-producing cells years before symptoms appear or insulin is needed. Finding type 1 diabetes early can greatly reduce the risk of diabetic ketoacidosis, or DKA, at diagnosis and may give people access to treatments such as teplizumab that can delay progression to clinical T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-convened-paper-outlines-first-international-consensus-guidance-on-general-population-screening-for-early-stage-type-1-diabetes-302875788.html XX Eating only between noon and 8 p.m. improved blood sugar control in a small study of adults with Type 1 diabetes and obesity, while avoiding an increase in serious complications. The promising findings offer the first evidence that time restricted eating could become another tool for managing the condition. For the study, Varady recruited adults with Type 1 diabetes who were also classified as obese After six months, the time-restricted eating group showed better blood sugar results than the calorie-reduction group. HbA1c, a blood test that reflects average blood sugar over the previous several months, fell by about 0.5% on average in the time-restricted group. Couple of things here – very small study, only 32 people in total, who were then randomly placed in three groups with different styles of eating. Also, the lead researcher says this is the first study of it’s kind for type 1 – which is obviously not true – you can do a quick google search or listen to past episodes of this show.. XX A large Danish study found that COVID-19 infection was associated with a slightly lower, rather than higher, risk of subsequently developing type 1 diabetes in people under age 30. Researchers studied more than 2,100 people diagnosed with T1D and found an overall 16% lower risk following a documented COVID infection, with the strongest association—a 42% reduction—seen 31 to 180 days after infection. The reduced risk appeared primarily among people who had not been vaccinated against COVID-19, although researchers cautioned that the vaccination findings were less certain. Importantly, this was an observational study, so it cannot show that COVID infection actually protects against type 1 diabetes or explain what caused the association. Researchers say the findings conflict with some earlier studies and should be investigated in other countries and populations. https://www.news-medical.net/news/20260908/COVID-19-linked-to-lower-subsequent-risk-of-type-1-diabetes.aspx XX Semaglutide, a medication widely used for type 2 diabetes and weight loss, may also provide an unexpected benefit for people with asthma. New research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain, found that semaglutide use was associated with a reduction in asthma attacks of nearly 40%. The study was led by Professor Chloe Bloom, Clinical Associate Professor in Respiratory Epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee. Exploring GLP 1 Drugs and Lung Health Dr. Bloom said: "GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity. Previous research suggests that they may have anti-inflammatory effects and may improve lung-related outcomes. However, asthma and COPD outcomes have not been included as outcomes in GLP-1 drug trials. "We wanted to use real-world health records to investigate whether people with asthma or COPD who started GLP-1 receptor agonists had fewer acute respiratory attacks." To investigate that question, the researchers analyzed electronic medical records from the UK. They carried out four parallel studies, each involving between 20,000 and 22,000 people who had started treatment with either a GLP-1 medication or a different type of diabetes drug known as a sulfonylurea. The results suggested that people with airway diseases such as asthma and COPD who received GLP-1 therapies experienced fewer asthma attacks and COPD flare-ups than comparable patients who were prescribed other diabetes medications. Semaglutide Showed the Strongest Effect Among the GLP-1 drugs examined, semaglutide appeared to stand out, particularly for people with asthma. Bloom explains: "The effect was strongest with semaglutide, especially in people with asthma, where use of semaglutide appears to be associated with nearly a 40% reduction in asthma attacks. Semaglutide also led to a 20% reduction in COPD flare-ups." The findings suggest that people who already qualify for GLP-1 receptor agonists because they have obesity or type 2 diabetes could potentially receive an additional benefit for their respiratory health. However, Bloom emphasized that the results are not enough to recommend these medications specifically as treatments for asthma or COPD. She explains: "The findings from this study are encouraging, but they should not change treatment decisions on their own. People with asthma or COPD should not start GLP-1 receptor agonists specifically for their lung condition outside current prescribing guidance. While the findings suggest that some people taking GLP-1 receptor agonists may experience fewer respiratory attacks, this needs confirmation in clinical trials." XX XX A large study suggests women with endometriosis may have a higher risk of developing type 2 diabetes. Researchers analyzed health records from nearly 3 million women in Utah and found those diagnosed with endometriosis were 46% more likely to develop type 2 diabetes than those without the condition. The association was strongest among women who had not yet reached menopause and those without obesity, a group typically considered at lower risk for type 2 diabetes. Certain forms of endometriosis, including those found outside the pelvic area, were associated with more than twice the risk. Researchers say more study is needed, but the findings suggest endometriosis may have health effects beyond the reproductive system and could eventually help identify women who may benefit from earlier diabetes screening. https://www.nih.gov/news-events/nih-research-matters/endometriosis-may-increase-type-2-diabetes-risk XX MiniMed files FDA submission for it’s first patch pump, with a planned launch next summer. To be called MiniMed fit, it would have a 300-unit insulin reservoir and would accommodate up to seven days of wear time. MiniMed also completed enrollment of a pivotal trial for a fully closed loop algorithm, which would calculate the amount of insulin a person needs throughout the day, even if they don’t announce meals or count carbohydrates. Interestingly, on an investor call, the CEO acknowledged that CGMs have been their – quote – Achilles’ heel for a very long time” and that their newest sensor has helped drive insulin pump growth. https://www.medtechdive.com/news/minimed-submits-new-patch-pump-for-fda-clearance/829313/ XX A new study based on national health registers in Denmark suggests starting statin treatment after a type 2 diabetes diagnosis could lower the risk of dementia, and it seems that the sooner patients did, the better. The research, published in The Lancet Regional Health, is an observational study, meaning it can find statistically relevant patterns at the population level, but doesn't necessarily explain what caused those patterns. The results, however, were interesting enough that the researchers, led by medical doctor Tummas Ternhamar of the Copenhagen University Hospital, are urging doctors to consider statin therapy when diagnosing type 2 diabetes patients. "Statins seem to be underused in patients with type 2 diabetes, despite their protective effects against cardiovascular disease." https://www.sciencealert.com/statins-linked-to-lower-dementia-risk-in-massive-type-2-diabetes-study XX Big sports news with type 1. Alezander Zverev wins Family was at the heart of Alexander Zverev's U.S. Open triumph on Sunday as the German saluted the members of his inner circle and paid a heartfelt tribute to his mother for refusing to let diabetes define his future. The top seed beat American Ben Shelton 6-3 7-6(2) 5-7 6-2 at Flushing Meadows to finish a spectacular year at ‌the Grand Slams in which he proved his doubters wrong by going from perennial nearly man to two-time major champion. Shortly after his victory, Zverev reserved special praise for his mother Irina, a former professional tennis player, and credited her with ensuring type 1 diabetes never limited his ambitions in life. "When your 4-year-old son is diagnosed with diabetes and doctors in the office tell you that life and sports will be very limited for that child, it takes a very strong mother to say 'my son will be whatever he wants to be'," Zverev said. "'If he wants to be a tennis player, ⁠he'll be a tennis player. If he wants to do something else, he'll do something else, but this illness will not define us'. XX Also, shout out to Garrett Mitchell (Center field Milwaukee Brewers) lives with Type 1 Diabetes and hit a grand slam immediately after having a failed insulin pump site. He was diagnosed with T1D at the age of 9. And I have a T1d mom friend who’s known him since he was a kid. Just great to see athletes talking about failed insulin sets like they’re just part of everyday life.. because they are. Btw it was the first grand slam for the brewers all year. XX The new Netflix movie The Runner is getting a bit of a side eye from some in the diabetes community… the Gal Gadot thriller features a child with type 1 but as usual, there are some weird inaccuracies. Ginger Vieria from Diabetes nerd has a great vide on this – I’ll link it up: but they’re saying things like Insulin Dispenser instead of pump.. and some other weird stuff.. but I’ve heard such bad things about this movie I’m not sure it’s worth watching just for this. Ginger’s video is though! /episode/index/show/diabetesconnections/id/42898240

Eversense 365 + twiist: New Data & What’s Next for the Implantable CGM 09/08/2026

Type 1 Diabetes Screening Has Changed. What You Need to Know Now (Bonus episode) 09/06/2026

In the News... Mounjaro update, CGM Medicare coverage shift, Metformin and aging study, Dolly Parton T1D connection and more! 09/01/2026

In the News... Mounjaro update, CGM Medicare coverage shift, Metformin and aging study, Dolly Parton T1D connection and more! On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don’t use insulin and a new study about using CGM when you don’t have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more... Check out all of Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don’t use insulin and a new study about using CGM when you don’t have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more.. that’s coming up right after this. (AD BREAK) Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Welcome to September! Want to let you know about a webinar I’m doing with Abbott later this month. That’s Sept 23 at 7pm ET. We’ll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved – more on that coming up. But please register – the link is in the show notes. So much going on over here – tomorrow night we have our Club 1921 in Charlotte, later this month Moms’ Night Out Detroit/Bloomfield and in October we’re going to Seattle. Please join us. More at d-c dot com slash events. Okay.. our top story this week: XX Another indication for Mounjaro – the FDA approved it to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro – the brand name of tirzepatide - is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. The approval was based on results from the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide). https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html XX The FDA approves the Libre Duo – the first device designed to continuously monitor both blood sugar levels and ketone levels in people with diabetes. The Libre Duo 10-Day Continuous Dual Glucose Ketone Monitoring System is now approved for those ages 2 and older. Until now, the agency said, people had to monitor ketone levels with separate tests that only provided a single measurement at one point in time. The new system combines blood sugar and ketone tests and monitors them continuously. Readings -- and alerts in case of dangerous trends -- are sent wirelessly to a smartphone app. The FDA previously granted "breakthrough device" status to the system, which is meant to expedite the device's development and review. https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/ XX Diabetes tech firms Dexcom and Abbott are watching closely for a Medicare coverage expansion that could significantly broaden access to their glucose sensors. The Centers for Medicare and Medicaid Services is expected to expand Medicare coverage of continuous glucose monitors to people with diabetes who do not take insulin. Currently, coverage is limited to people with Type 1 or Type 2 diabetes who take insulin or have a history of problematic low blood sugar. Dexcom CEO Jake Leach told investors in a late July earnings call that the company expects to hear back from the CMS before the end of the year, with coverage going into effect in mid-2027. Dexcom presented results of a randomized, controlled trial earlier this summer at the American Diabetes Association’s Scientific Sessions that it expects will support the CMS’ decision. The 26-week study found that people who used a CGM had a larger hemoglobin A1C reduction than the control group and spent five more hours per day in a normal glucose range than the control group. XX A new study suggests continuous glucose monitors (CGMs) may offer benefits for people with type 1 diabetes that go beyond improving blood sugar and reducing hypoglycemia. Researchers analyzed health records from more than 8,400 adults with type 1 diabetes receiving care through the Veterans Health Administration. Over one to four years of follow-up, people who started using a CGM had a 10% to 16% lower risk of death from any cause compared with those who did not use one. The association appeared strongest among people over age 65 and those who were not using insulin pumps. Researchers did not find meaningful differences based on A1C, race or ethnicity, or frailty. Importantly, this was an observational study using medical records, not a randomized clinical trial, so it cannot prove that CGM use directly caused the lower death rate. But the findings suggest CGM may have important long-term health benefits beyond glucose management.https://visualize.jove.com/42319755-continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-onset-type-1-diabetes-patients-a-target-trial-emulation-study-within-the-veterans-health-administration XX We’ve been talking about people without diabetes using CGMs for a long time.. now a new study weighs in. Research published in JAMA finds that this wellness trend isn’t helpful for people without a diabetes diagnosis. They found that the strongest evidence for CGM use is for people who are already living with diabetes, but not for those without the condition who use them for wellness purposes. It’s also worth noting, though, that this new study is a narrative review. This means that the researchers drew their conclusions from the findings reported in several other studies. More randomized controlled trials would be necessary to see whether there are any meaningful health benefits of using a CGM if you don’t have diabetes. Dower also warned that constantly monitoring your blood sugar when you don’t have diabetes could lead to unintended health anxiety. In some cases, you may even make accidental lifestyle changes that could be harmful. “[Blood sugar] spikes may occur after meals, but if this leads someone to replace healthy food such as fruit with unhealthy food such as something high in fat but low in carbohydrate, the glucose information has done more harm than good,” Dower said. https://www.verywellhealth.com/blood-sugar-monitor-for-people-without-diabetes-12058575 XX Could metformin somehow influence the biological processes that drive aging? A new review found evidence that metformin may affect several key features of aging, including how cells use energy, inflammation, cellular damage and even some changes in gene activity. Animal studies have shown longer lifespans or improvements in markers of biological aging, while some human studies have also found promising results. But researchers say there’s still no proof that metformin actually slows aging or helps healthy people live longer. Most human research has involved people with diabetes or other health conditions, and one large trial found that while metformin helped prevent type 2 diabetes, it did not reduce cancer, cardiovascular disease or deaths. Researchers say larger clinical trials in people without diabetes are needed to determine whether metformin can truly extend healthy lifespan—or whether its benefits are primarily related to preventing and treating specific diseases. https://www.technologynetworks.com/drug-discovery/news/metformin-may-influence-longevity-through-the-gut-microbiome-and-epigenetic-changes-416035 XX More to come including more research on a spice thought to help diabetes, predictions about the number of people who may be living with type 1 in the years to come around the world, and a connection I didn’t know about between diabetes and Dolly Parton. XX A compound found in turmeric may help protect blood vessels from some of the damage caused by Type 1 diabetes. In rats, curcumin reduced inflammation, improved cellular signaling, and restored vascular health to levels resembling those of nondiabetic animals. The results hint at a possible new way to reduce the long-term cardiovascular risks of diabetes, but human trials are still needed. Curcumin, the natural compound responsible for turmeric's vivid yellow color, is widely studied for its anti-inflammatory and antioxidant properties. https://www.sciencedaily.com/releases/2026/08/260824065543.htm XX New research estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049. This will be presented at EASD, the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2 The USA will see an increase of over half a million, going from 1,492,825 to 2,055,235. The authors suggest that the reasons for the predicted high incidence and prevalence in 2049 in countries such as Australia, US, UK are likely to be a combination of genetics, environmental triggers and also high case detection rates (due to the good health care infrastructure here and in other HIC). Unlike previous estimates, the DIAMOND-T1D model takes historical patterns of insulin availability into account and aims to provide global, regional and country-specific estimates of T1D incidence, prevalence and mortality from 1900 to 2050. Although the majority of people with T1D live in high-income countries (HIC) and middle-income countries (MIC), the largest relative increase in the T1D prevalence is expected to occur in LIC as access to insulin, glucose monitoring and survival all improve in those countries. https://www.news-medical.net/news/20260828/Type-1-diabetes-cases-projected-to-increase-worldwide-by-2049.aspx XX Early initiation of statins after a diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study published in The Lancet Regional Health – Europe. According to the Lancet Commission, nearly half of dementia cases could theoretically be prevented by eliminating 14 risk factors. "Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor," From Danish registers, researchers identified 132,585 statin-naive individuals who developed type 2 diabetes from 2006 through 2019, with follow-up until the end of 2021. Medical records were searched for diagnoses of all-cause dementia. A clone-censor-weight design was used to analyze dementia incidence in patients with no statin initiation within five years after diagnosis, in those with early statin initiation within one year and in those with late statin initiation between one and five years after diagnosis. https://medicalxpress.com/news/2026-08-early-statins-diagnosis-diabetes-dementia.html XX We are heartbroken over the loss of our friend Dolly Parton. Dolly was a beloved icon whose extraordinary generosity, warmth, and compassion touched countless lives, including those of the Children’s Diabetes Foundation and the Barbara Davis Center for Diabetes. Her support of The Carousel Ball and Carousel of Hope Ball reflected her deep commitment to helping children and families affected by type 1 diabetes. Beyond her remarkable talent, Dolly will be remembered for the kindness and joy she shared so generously with others. Our hearts are with her family, friends, and all who loved her as we celebrate her extraordinary life and lasting legacy. She will be deeply missed. /episode/index/show/diabetesconnections/id/42620205

Live Free with T1D: How to Stop Diabetes Stress From Shrinking Your Life, with Dr. Mark Heyman 08/25/2026

In the News.. new weekly basal, retatrutide lawsuits, childhood T1D studies, run for T1D research and more! 08/18/2026

Inside the new Flex Pump - and what’s coming next from MiniMed with Chief Technology Officer Ali Dianaty 08/11/2026

In the News... Lantus Shortage, Pill for T1D Studied, Ring Measures Glucose in Sweat, Call Her Daddy Host Shares Diabetes Diagnosis, Cookie Queens Movie and more! 08/04/2026

In the News... Lantus Shortage, Pill for T1D Studied, Ring Measures Glucose in Sweat, Call Her Daddy Host Shares Diabetes Diagnosis, Cookie Queens Movie and more! On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and a new documentary about Girl Scout cookies shines a spotlight on T1D. Don't miss our upcoming events! Moms' Night Out in Detroit and Seattle, Club 1921 in Charlotte and Phoenix: Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Transcript: (Stacey Track) On this episode of Diabetes Connections In the news… Sanofi acknowledges an insulin shortage, a new oral therapy for type 1 moves along in research, could there be an actual, accurate, non-invasive CGM in the works, ADA conflict continues and I can’t wait to tell you about Cookie Queens.. that’s coming up right after this. (AD BREAK) Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We are still looking for your community commercials. These are 30–60 second audio spots created by members of the diabetes community to share: Events you’re organizing: a fundraiser, walk, or local meetup Products you’ve created: maybe you’ve written a book, have a Substack, designed a T1D-friendly gadget, or launched a small business Helpful projects or resources: things you think others in our community should know about It’s your chance to share what you’re doing and help others get connected! Full instructions are on the website. While you’re there please check out our events. We’re turning toward fall and we have a lot going on – MNO and Club 1921. Okay.. our top story this week: XX I want to talk about Cookie Queens! It might not sound like a hard news story.. but It’s my show and I can’t wait to watch this. This move follows four Girl Scouts ages 5-12 during cookie season. One of the girls has type 1 – they don’t mention it in the trailer, but you can see her omnipod. Here’s a clip: Start the very beginning and stop after “I want to be a supreme court justice.” (stop after the “oh..laughter” https://www.youtube.com/watch?v=nnSQS43Eil8 Viewers meet Ara from San Diego, CA (5), Shannon Elizabeth from El Paso, TX (8), Nikki from Chino, CA (9), and Olive from Charlotte, NC (12). Ara has Type 1 diabetes and is shown taking insulin, refilling her pump before bed, and determining with her dad how to sample the cookies she’s selling while keeping her blood sugar levels safe. Thumbs down to the Hollywood reporter dot com. In their review they say.. “if this film were itself a baked good, Ara would need to be careful because one bite could cause hyperglycemia or even diabetic ketoacidosis. It’s just that sweet.” Cookie Queens comes out this month. https://www.hollywoodreporter.com/movies/movie-reviews/cookie-queens-review-prince-harry-meghan-markle-girl-scouts-1236484555/ trailer: XX Supply issues for Lantus SoloStar pens being acknowledged by Sanofi. The company says it’s experiencing "a period of intermittent supply due to increased demand. The company said the increase in demand is being driven by "broader market dynamics," but did not provide additional details. Sanofi said the situation is temporary and is expected to improve over the coming weeks. The company said Lantus U-100 vials and Toujeo U-300, which contain the same active ingredient, remain available. https://www.wral.com/news/local/common-insulin-pen-faces-supply-issues-amid-rising-demand-july-23-2026/ XX The University of Alabama at Birmingham startup TIXiMED Inc. has launched the next phase of clinical testing for a novel oral therapy for Type 1. For now called TIX100, a small-molecule drug designed to inhibit a protein linked to pancreatic beta-cell loss and diabetes progression. The new double-blind, randomized, placebo-controlled study will evaluate the drug’s safety, tolerability and pharmacokinetics. Researchers will enroll 18 healthy participants across three dose cohorts at a single United States study site. Participants will receive either TIX100 or a placebo twice daily for 28 days, followed by a seven-day follow-up period. Six participants making up the first cohort have been successfully enrolled thus far. In addition to its potential use in Type 1 diabetes, TIX100 may have applications in Type 2 diabetes and obesity. A recent study found that the drug prevented weight regain and preserved lean muscle mass after discontinuation of GLP-1 therapies in preclinical models. https://www.uab.edu/news/research-innovation/startup-advances-novel-oral-type-1-diabetes-therapy-to-next-phase-of-human-testing XX Researchers at the University of California San Diego say they have developed and validated a Continuous Health Analyzing Ring Module (CHARM), a compact, fully integrated wearable smart ring capable of continuous real-time monitoring of multiple biomarkers in sweat. The wearable device can simultaneously measure up to four biomarkers, including glucose, ketone, uric acid, lactate, ascorbic acid, and alcohol, to provide real-time insights into metabolic health. The study is published in Nature Communications. They say CHARM device contains all necessary biomarker sensors, low-power electronics, and a flexible battery. The left compartment of the device is designed to draw sweat passively using an osmotic hydrogel, a soft polymer that creates a pressure gradient to pull fluid from the skin painlessly. The sweat is then analyzed by multiplexed electrochemical sensor arrays within the same compartment, leading to simultaneous and real-time tracking of four biomarkers at a time. The right compartment of the device contains a flexible zinc-silver oxide rechargeable battery that supplies power for up to 12 hours of operation between charges. Biomarker information generated through sensors is wirelessly transferred to a connected Bluetooth-enabled device for real-time display The findings indicated that the device performed well in initial temperature, cytotoxicity, and on-body compatibility tests. It also demonstrated high analytical accuracy in preliminary studies involving healthy participants and individuals with type 1 diabetes, highlighting its potential for non-invasive metabolic monitoring. The calculated estimated sweat-based blood glucose concentration showed a mean absolute relative difference of approximately 13.7% against its corresponding blood concentration values. The device needs further validation in diverse clinical settings and across large diabetic cohorts. https://www.news-medical.net/news/20260727/Prototype-smart-ring-tracks-multiple-sweat-biomarkers.aspx XX Hotter weather and rising temps appear to increase the short term risk for low blood sugar in adults with type 1. An analysis of more than 32 million continuous glucose monitor (CGM) readings from nearly 700 adults with T1D in the UK showed a 26% greater risk for hypoglycemia at a temperature of 25 °C (77 °F) than at 13 °C (55.4 °F). Hypoglycemia was defined as a glucose level < 3.9 mmol/L (70 mg/dL). The study included 679 individuals with T1D and 32,966,282 CGM readings collected between February 23, 2017, and August 8, 2024. Participants had a mean age of 46.4 years and a mean T1D duration of 23.7 years. The researchers observed strong seasonal patterns, with lower odds of hypoglycemia in late winter and early spring, followed by a peak during the summer. The lowest risk occurred on Mondays. The odds then increased over the course of the week and peaked toward the weekend, with a significant odds ratio of 1.14 on Saturdays compared with Mondays. Increases in hypoglycemia were observed during both hot and cold weather, but the association was stronger for heat. The net odds ratio was 1.26 at 25 °C compared with 13 °C. https://www.medscape.com/viewarticle/when-temperatures-climb-hypoglycemia-risk-rises-type-1-2026a1000q4r XX Seven weeks after the expulsion of five diabetes experts from the American Diabetes Association conference, controversy continues. More than 200 members now calling for two ADA leaders to resign. In response, the ADA delivered its own message Tuesday, expressing appreciation for members’ patience while a report is prepared. The resignation demand, sent last week in an open letter to the ADA board of directors, calls for the removal of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani. It also urges “an independent investigation into the events of the 2026 Scientific Sessions in New Orleans, a full apology to the five colleagues removed from the meeting, and the restoration of editorial independence at Diabetes Care,” an ADA scientific journal. https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/ XX XX Still to come, , a new link between diabetes and dementia, device updates, and why you might want to start rooting for the Red Sox.. XX New study says that people diagnosed with type 1 diabetes (T1D) before the age of 10 years had a 37% higher risk of developing all-cause dementia later in life than those diagnosed between ages of 18 and 30 years. These researchers used a Swedish national register of 43,440 individuals with T1D (mean age at cohort entry, 33 years; 44% women) Worth noting a couple of things.. the mean age in this study was 33 – so the people who were diagnosed under the age of ten would not have had access to current technology – no CGMs or AID systems. And while the study says it’s 37% higher for the younger group, the actual rate was still very low. As always, I’ll link to the study so you can learn more. My obvious bias here to look for a silver lining because I have a son who diagnosed with T1D at age 2. https://www.medscape.com/viewarticle/type-1-diabetes-onset-before-age-10-tied-higher-risk-2026a1000pir XX Researchers have developed a machine learning model that uses routine clinical information to detect diabetes and distinguish between type 1, type 2, prediabetes, and diabetes caused by pancreatic disease. The model performed well in early testing, but researchers say it still needs to be validated in independent patient groups before it could be considered for use in diabetes screening or clinical care. It did not assess clinical utility, patient outcomes, or quality of life. https://www.news-medical.net/news/20260729/Researchers-train-AI-to-detect-diabetes-and-assign-four-diagnostic-labels.aspx XX Trinity Biotech and Latch Medical are teaming up to explore combining CGM with precision drug delivery technology for diabetes, obesity, and other metabolic conditions. The companies hope real-time glucose data from Trinity's CGM+ sensor could eventually help guide more personalized treatment decisions and medication delivery. Trinity's CGM+ is still in development, with a pivotal clinical trial planned for later this year. https://www.drugdeliverybusiness.com/trinity-biotech-collab-cgm-drug-delivery/ XX The FDA selects Dexcom as the first participant in a new digital health pilot that will exempt certain digital health devices from FDA premarket authorization requirements while collecting real world data through a complementary Medicare program. Dexcom, plans to implement an artificial intelligence-enabled glucose health program through the pilot. The program is intended to help screen for prediabetes and Type 2 diabetes. The company plans to integrate data from its sensors, including its prescription G7 CGM and its over-the-counter Stelo device, along with contextual health information such as nutrition, physical activity, sleep and stress. The FDA announced plans for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, pilot last year amid a broader push for adoption of digital health and wearables. It coincides with a new program by the CMS to fund the use of digital technologies for managing chronic conditions. https://www.healthcaredive.com/news/fda-names-dexcom-as-first-participant-in-digital-health-pilot/826215/ XX Medicare and Medicare Advantage beneficiaries now have access to the new MiniMed Flex insulin pump. Beneficiaries can now access the MiniMed Flex and its latest sensor portfolio, which currently includes the Simplera Sync sensor, a disposable, all-in-one sensor with easy two-step insertion. The company plans to roll it out with the Instinct sensor, made by Abbott, later this summer. It also added Abbott’s dual glucose-ketone sensor (still investigational in the U.S.) to its portfolio this year. Flex picked up FDA clearance in March and the company announced the initial commercial rollout of the pump last month. https://www.drugdeliverybusiness.com/minimed-flex-pump-now-available-medicare/ XX Eli Lilly expands it’s partnership with Resilience – the makers of the KwikPen device. Through the investment, Resilience will significantly increase U.S. production of Lilly’s KwikPen injectable device for diabetes and obesity medicines. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. https://www.biospace.com/deals/lilly-and-resilience-invest-750m-in-diabetes-and-obesity-drug-device-supply XX Alex Cooper – the host of the top podcast Call her Daddy – announced she’s been diagnosed with gestational diabetes. “When I got this diagnosis, the first couple days, I was really hard on myself,” the 31-year-old admitted. “It felt very isolating, like, as much as my family and my husband and everyone was there for me I just felt like, it’s me on an island.” She says she found an online community that’s been helping. In sharing her experience, she hoped it would alleviate the stress. https://www.eonline.com/news/1434556/pregnant-alex-cooper-shares-isolating-gestational-diabetes-diagnosis XX Several amazing diabetes non profits are vying for big charity dollars from the Boston Red Sox. The IMPACT Awards provide Red Sox fans with the chance to nominate their favorite, most impactful nonprofit organization serving New England for their opportunity to win a grant from the Red Sox Foundation. In 2026, the IMPACT Awards will focus on organizations that are supporting research and providing awareness, advocacy, and services to people with diabetes. Check out all the charities and vote for your favorites – you’ve heard of so many of these I promise – at the link in the episode show notes, . https://www.mlb.com/redsox/community/red-sox-foundation/impact-awards?partnerId=redirect-bos-impact /episode/index/show/diabetesconnections/id/42299010

Highs, Lows, & Hormones: What every woman with T1D should know, with Melissa Slemp 07/28/2026

In the News... More ADA Controversy, Insulin pricing bill, Setback for GLP-1 and T1D, Dexcom 15-day expands converage, and more! 07/21/2026

Omnipod + Calm: A New Tool for the Mental Load of Type 1 Diabetes 07/16/2026

Raising a Child with Type 1 Diabetes Without Losing Yourself 07/14/2026

800 Episodes Later: What I've Learned From the Diabetes Community 07/07/2026

In the News... Tzield, Retatrutide, New Clues About Type 1 and more! 06/30/2026

In the News... Tzield, Retatrutide, New Clues About Type 1 and more! It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Transcript & links: Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/ XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy. In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings. Following is a transcript of his remarks: What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses. Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity]. And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%. However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment. Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment. Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure. And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin. So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment. So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it’s not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: “The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients.” https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance. Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They’ve added that to include people diagnosed with type 1 who’ve been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care. Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing. The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season. https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/ /episode/index/show/diabetesconnections/id/41910570

Inside Diabetes Will's Way: Helping Families Afford the Care They Need 06/23/2026

In the News... Tzield approved for newly diagnosed T1D, GLP-1 studies for type 1, ADA 2026 highlights and more! 06/16/2026

In the News... Tzield approved for newly diagnosed T1D, GLP-1 studies for type 1, ADA 2026 highlights and more! It's In The News - a look at the top diabetes stories and headlines happening now! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcript: fall Detroit and Seattle. Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that’s what we used to just call type 1. It’s the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it’s the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells. The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You’ve probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That’s , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet’s current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It does not require carb-counting or insulin bolusing ahead of meals. Physicians also don’t need to program the starting settings. XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that’s all to come right after this. -- Back to the news.. XX Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology. -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings. XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They’re also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg’s family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. “Becoming a professional tennis player was always my dream,” Zverev shared in an article posted by Medtronic. “Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That’s why I’m partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want.” He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries.” /episode/index/show/diabetesconnections/id/41649685

Inside the ADA Scientific Sessions Protest & Aftermath with Dr. Desmond Schatz 06/12/2026

T1D and Celiac: Practical Tips from a Family Who's Been There 06/09/2026

BONUS: Dexcom updates & news from ADA with CEO Jake Leach 06/07/2026

BONUS Episode: Afrezza Approved for Kids: A Deep Dive Into Inhaled Insulin with INHALE-1 Lead Investigator Dr. Jamie Wood 06/04/2026

In the News.. Inhaled Insulin Approved for Kids, CGM + Ketone Monitor, Food Coloring & Diabetes Study, Device Recalls and more! 06/02/2026

In the News.. Inhaled Insulin Approved for Kids, CGM + Ketone Monitor, Food Coloring & Diabetes Study, Device Recalls and more! It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcripts: Welcome! I’m your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We’ll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We’ve got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind’s afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients. The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: “Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option.” Lots more to come on this – we’re working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it’s such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They’re calling this Libre Duo and Libre Duo 10 Day, and it’s designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic. Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action. The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling. Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said. People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics’ interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association’s Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet’s patch pumps on the market. It would have a 200-unit insulin reservoir. Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall. https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it’s coverage list – with it’s Caremark PBM. They also added Foundayo, Lilly’s obesity pill. CVS had dropped Lilly’s Zepound last summer but kept competitor Wegovy. It’ll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers now cover Lilly's full obesity medicine portfolio. More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers. Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). “Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence,” the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women. Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea. While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. “Tidepool has always focused on making diabetes data more accessible and actionable,” said Brandon Arbiter, CEO. “We’re excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters.” Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool’s existing EHR integration capabilities. Direct Connect is part of Tidepool’s ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes. The feature is now available in the Connection Hub of the Epic Showroom. https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX /episode/index/show/diabetesconnections/id/41492405

SAB Bio’s Safeguard Study: A New Way to Approach Type 1 Diabetes Delay and Prevention 05/26/2026

In the News... Dexcom G8 details, GLP-1 T1D studies, Pump + CGM all-in-one update, cannabis for diabetes and more! 05/19/2026

In the News... Dexcom G8 details, GLP-1 T1D studies, Pump + CGM all-in-one update, cannabis for diabetes and more! It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Episode transcript: XX Dexcom announces some features of it’s next generation CGM – the G8. We’ve been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they’re calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It’s an interesting space to watch.. btw, analyte is just a medical word for the specific thing you’re measuring – the target of the test you’re running. we’re going to hear that word a lot I think.. Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that’s investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack’s active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology. PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics’ CGM. PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems. Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It’ll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/-- XX Diabeloop just got CE Mark approval for DBLG2 integrations – it’s latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it’s integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps “available soon.” Running on a user’s smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/ XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis. METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively. "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease. XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes. The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. “This study is the tip of the iceberg,” said Dr. Evans-Molina. “We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data.” https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients. “This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied,” said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center. Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival. What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report. The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes. GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment. “Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings,” said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health. What’s next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials. “Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making,” Fuemmeler said. XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. “We would think that chronic cannabis users would be eating more and weigh more, but it’s just the opposite,” DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body’s endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here’s what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes. One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes /episode/index/show/diabetesconnections/id/41331730

“Every trip is a learning experience” Advice from travel-loving T1D parents, Sarah Steward Holland and Nicholas Holland 05/12/2026

In the News.. Tzield approved for toddlers, generic Ozempic, Omnipod & Tandem updates, T1D Barbie honored... and more! 05/05/2026

In the News.. Tzield approved for toddlers, generic Ozempic, Omnipod & Tandem updates, T1D Barbie honored... and more! It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more. Announcing Community Commericals! Learn how to Don't miss our in-person events: Learn more about Please visit our Sponsors & Partners - they help make the show possible! from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/ XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community. It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada ‌has approved the first generic version of Danish ⁠drugmaker ⁠Novo ‌Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. XX Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028. XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes insulin leakage. Patients using the affected devices could risk experiencing high blood glucose levels due to insufficient insulin delivery, the Acton, Massachusetts-based MedTech disclosed in a statement late Thursday. The company has already notified the FDA about the recall, which it said will affect nearly 1.5% of Omnipod 5 pod units it manufactures annually. The customers were advised to immediately seek a product replacement at no cost if a Pod from a defective lot is currently in use. XX Tandem Diabetes Care (Nasdaq:TNDM) gets FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy. The FDA cleared the company’s Control-IQ AID technology for use in what they call: pregnancy complicated by type 1 diabetes mellitus. Tandem says t:slim X2 and Mobi are the first and only commercially available AID systems cleared for use during pregnancy in the U.S. https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/ XX Tandem also issued an urgent medical device correction for a software problem with its Mobi insulin pumps. The malfunction may cause insulin delivery to stop, causing high blood sugar if not addressed, the Food and Drug Administration said in a Wednesday recall notice. We told you about this back in October when Tandem sent a letter to customers notifying them of the fault and instructing them to update their pump software as soon as possible. The FDA now issued a class one recall, the most serious type. We just released a bonus episode all about Tanem – tubeless mobi and what else is in the pipeline. You can listen to that wherever you are listening to this.. it’s the episode just before this one. XX Switching CGMs didn’t make a measurable difference for adults using MiniMed’s pump system. In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to Instinct by Abbott were able to maintain a time in range of greater than 75%. “When it comes to the automated insulin delivery system ... I think the sensor matters less and the system matters more,” Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said during a presentation. “Having a different sensor with the system, I think the [glycemic] outcomes will still be what you want.” I’m including this because the headline here seemed to indicate no CGM makes a difference, but this study only looked at two. https://www.healio.com/news/endocrinology/20260401/switching-cgm-sensors-does-not-impact-glycemic-outcomes-with-automated-insulin-delivery XX Vitamin D supplementation may help delay or prevent disease progression in people with prediabetes.. in people who have specific variants in their vitamin D receptor gene. This was found after a second look at large study where researchers found vitamin d really did make a difference.. a second look with people who had a specific gene variation had much better results. “More research is needed to see if there are other factors that are associated with risk reduction.” https://www.medicalnewstoday.com/articles/vitamin-d-supplements-help-prevent-type-2-diabetes-right-gene-variants XX Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. Eversense 365 is the world’s first 365-day CGM system. It also holds clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems, like the Sequel Med Tech twiist system. The company said it made Eversense 365 available to the first patients in Sweden. It plans to bring the sensor to Germany, Spain and Italy in the coming weeks https://www.drugdeliverybusiness.com/senseonics-launches-eversense-365-europe/ XX A machine learning model can improve genetic prediction of type 1 diabetes by as much as 10%, show results from a University of California, San Diego study. The researchers used the machine‑learning model T1GRS to improve on a gold standard polygenic genetic risk score used to predict who is likely to develop the condition called GRS2. The GRS2 polygenic risk score has been widely tested and can be used to predict newborns who are at high risk of developing type 1 diabetes. While early prediction can’t necessarily stop the disease it can help to prevent emergencies like diabetic ketoacidosis at diagnosis, allow families time to prepare and could allow use of therapies to delay onset of the condition. In this study, Gaulton and colleagues carried out a genome‑wide association study in 20,355 people with type 1 diabetes and 797,363 non‑diabetic Europeans, as well as a further analysis around the MHC region in 10,107 diabetic and 19,639 nondiabetic individuals. https://www.insideprecisionmedicine.com/topics/molecular-dx/machine-learning-tool-helps-improve-type-1-diabetes-prediction/ XX Sen. Mark Warner (D-Va.) said Monday that he will return to the upper chamber this week after taking time off for the death of his daughter, Madison. The Virginia senator wrote on the social platform X, “As we remember our incredible daughter, Maddy, my family has been deeply touched by the outpouring of support we’ve received. Thank you to everyone for your kind words.” Madison Warner, 36, died earlier this month after a decades-long battle with juvenile diabetes and other health issues. Mark Warner and his wife, Lisa Collis, wrote in a statement last Monday that they were “heartbroken beyond words” by their daughter’s passing. On Monday, the former Virginia governor said his daughter “was a deeply empathetic and engaged person” and that “as recently as the day she passed, she was full of ideas and suggestions” for him, including how he could improve his social media presence. “She used to say to me: ‘Dad, you have the power — you have to use it.’ She pushed me to make the most of my position, to use my seat in the Senate to help people in meaningful ways,” he added. “If I can find any solace during this time, it’s that I have the enormous privilege to serve Virginians and the responsibility to keep working for a better, more just world in Maddy’s name.” Warner concluded, “I look forward to returning to the Senate this week and continuing that essential work.” Madison Warner is survived by two younger sisters. An estimated than 2.1 million Americans, including about 314,000 children and adolescents younger than age 20, have diagnosed type 1 diabetes as of March — which is what juvenile diabetes is commonly called — according to the CDC’s National Diabetes Statistics Report. An estimated 11 million U.S. adults have undiagnosed diabetes, the report notes. Symptoms of type 1 diabetes include feeling more thirsty than usual, urinating a lot, bed-wetting in children who have never done so, feeling very hungry and losing weight without trying, according to the Mayo Clinic. https://thehill.com/homenews/senate/5851605-mark-warner-diabetes-death/ XX Mattel, Inc. and Breakthrough T1D just won a Gold Halo Award for Best Cause Product Initiative for the launch of the first Barbie with T1D. The Halo Awards recognize the most outstanding corporate social impact efforts over the past year. /episode/index/show/diabetesconnections/id/41148080

Inside Tandem’s Next Chapter: Tubeless Mobi, 7-Day Wear & More with VP of Product Management Marisa Fienup 05/01/2026

Diabetes Connections | Type 1 Diabetes

TOPICS